However, given that ovarian cancer cells often exhibit BRCAness (due to defects in homologous recombination) [46], [80], a phenotype that renders cells exquisitely sensitive to PARP inhibitors [81], it remained an unanswered question whether PARP inhibitors would also sensitize to FdUrd in colon cancer cells, which do not have defects in homologous recombination. This evidence concerns the gene PARP1 and colonic neoplasm.